EZH2 and non-Hodgkin lymphoma: EZH2 inhibitors EPZ-5687 [13] from Epizyme® and GSK-2816126 [14] from GlaxoSmithKline® for the treatment of non-Hodgkin's lymphoma are currently in clinical phases I/II and I, respectively.